QuintilesIMS Changes Name to IQVIA

Nov 10, 2017
By BioPharm International Editors

On Nov. 6, 2017, QuintilesIMS announced that it has changed its name to IQVIA, and will operate as a contract research services provider specializing in technological and analytical solutions for life sciences and healthcare companies. Starting Nov. 15, 2017, equity shares of the company will trade on the New York Stock Exchange under the new name and new ticker symbol “IQV.”

According to the company, the rebranding resulted from the merger of QuintilesIMS and IMS Health in October 2016.

“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward,” said IQVIA CEO and chairman Ari Bousbib, in a company press release. “Our clients have been instrumental in our becoming IQVIA. IMS Health and Quintiles came together because our clients were asking for better, faster ways to bring innovations to patients and capture the improvements the industry has been pursuing for years. Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings.”

Following this rebranding, the company, comprising of 55,000 employees in more than 100 countries, plans to advance its human data science capabilities with a focus on improving clinical development, data security, and privacy protection through its services.

Source: IQVIA

native1_300x100
lorem ipsum